# Erratum to “Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease” [J Prev Alzheimers Dis 2025;12(4): 100082]

**Authors:** Erika N. Cline, Daniel Antwi-Berko, Karen Sundell, Elizabeth Johnson, Maddelyn Hyland, Hao Zhang, Hugo Vanderstichele, June Kaplow, Robert A. Dean, Erik Stoops, Eugeen Vanmechelen, Marleen J.A. Koel-Simmelink, Charlotte E. Teunissen, Gopalan Sethuraman, Todd Feaster, Eric Siemers, Jasna Jerecic

PMC · DOI: 10.1016/j.tjpad.2025.100217 · The Journal of Prevention of Alzheimer's Disease · 2025-06-06

## Full-text entities

- **Diseases:** AD (MESH:D000544)
- **Chemicals:** ACU193 (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12321610/full.md

---
Source: https://tomesphere.com/paper/PMC12321610